Immix Biopharma Reports on Shareholder Vote
Ticker: IMMX · Form: 8-K · Filed: Jun 23, 2025 · CIK: 1873835
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
TL;DR
Immix Biopharma held a shareholder vote on June 20th; details filed today.
AI Summary
Immix Biopharma, Inc. filed an 8-K on June 23, 2025, reporting on a matter submitted to a vote of its security holders on June 20, 2025. The filing details the company's corporate structure and operational information, including its principal executive offices in Los Angeles, California.
Why It Matters
This filing indicates a significant corporate event involving a vote by security holders, which could impact the company's governance or strategic direction.
Risk Assessment
Risk Level: low — The filing is a routine 8-K reporting a shareholder vote, with no immediate financial or operational risks disclosed.
Key Players & Entities
- Immix Biopharma, Inc. (company) — Registrant
- June 20, 2025 (date) — Date of earliest event reported
- June 23, 2025 (date) — Date of report
- Los Angeles, CA (location) — Principal executive offices
FAQ
What specific matter was submitted to a vote of Immix Biopharma's security holders on June 20, 2025?
The filing does not specify the exact matter voted upon, only that a submission to a vote of security holders occurred on June 20, 2025.
When was the Form 8-K filed with the SEC?
The Form 8-K was filed on June 23, 2025.
What is Immix Biopharma's principal executive office address?
The principal executive offices are located at 11400 West Olympic Blvd., Suite 200, Los Angeles, CA 90064.
What is Immix Biopharma's telephone number?
The registrant's telephone number is (310) 651-8041.
What is the company's state of incorporation?
Immix Biopharma, Inc. is incorporated in Delaware.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 23, 2025 regarding Immix Biopharma, Inc. (IMMX).